Insider · CIK 0001658080
Cedric Francois
ceoofficerdirector
Files at APLS (Apellis Pharmaceuticals, Inc.). First filing Jan 14, 2025, latest Jan 23, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 10
$0 bought, $11M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 59Moderate | Apellis Pharmaceuticals, Inc. | $592k 27,192 shares | -9% | - | |
| 51Moderate | Apellis Pharmaceuticals, Inc. | $162k 8,182 shares | -3% | - | |
| 53Moderate | Apellis Pharmaceuticals, Inc. | $226k 10,186 shares | -3% | - | |
| 75Notable | Apellis Pharmaceuticals, Inc. | $6.4M 225,000 shares | -42% | - | |
| 14Weak | Apellis Pharmaceuticals, Inc. | $399k 19,725 shares | -6% | - | |
| 33Weak | Apellis Pharmaceuticals, Inc. | $2.8M 139,365 shares | -29% | - | |
| 49Moderate | Apellis Pharmaceuticals, Inc. | $83k 2,824 shares | -1% | - | |
| 56Moderate | Apellis Pharmaceuticals, Inc. | $412k 13,551 shares | -3% | - | |
| 52Moderate | Apellis Pharmaceuticals, Inc. | $180k 6,007 shares | -2% | - | |
| 52Moderate | Apellis Pharmaceuticals, Inc. | $179k 6,247 shares | -2% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | APLS Apellis Pharmaceuticals, Inc. | GGift Common Stock | -64,869 | $0.00 | $0 | 425,968 | Mar 13, 2026 |
| Mar 11, 2026 | APLS Apellis Pharmaceuticals, Inc. | GGift Common Stockindirect: Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) | +64,869 | $0.00 | $0 | 372,815 | Mar 13, 2026 |
| Feb 3, 2026 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock | +8,840 | $3.76 | $33k | 490,837 | Feb 5, 2026 |
| Feb 3, 2026 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -8,840 | $0.00 | $0 | 0 | Feb 5, 2026 |
| Jan 28, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +195,952 | $0.00 | $0 | 481,997 | Jan 30, 2026 |
| Jan 22, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -27,192 | $21.77 | $592k | 286,045 | Jan 23, 2026 |
| Jan 20, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -8,182 | $19.79 | $162k | 313,237 | Jan 21, 2026 |
| Jan 13, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -10,186 | $22.19 | $226k | 321,419 | Jan 15, 2026 |
| Aug 27, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) | -175,037 | $28.19 | $4.9M | 357,909 | Aug 29, 2025 |
| Aug 28, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) | -49,963 | $28.39 | $1.4M | 307,946 | Aug 29, 2025 |
| Jul 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +8,997 | $4.31 | $39k | 351,330 | Jul 18, 2025 |
| Jul 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -19,725 | $20.21 | $399k | 331,605 | Jul 18, 2025 |
| Jul 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,997 | $0.00 | $0 | 100,538 | Jul 18, 2025 |
| Jul 14, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +65,203 | $4.31 | $281k | 480,898 | Jul 16, 2025 |
| Jul 14, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -137,465 | $20.19 | $2.8M | 343,433 | Jul 16, 2025 |
| Jul 15, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +800 | $4.31 | $3,448 | 344,233 | Jul 16, 2025 |
| Jul 15, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -1,900 | $20.09 | $38k | 342,333 | Jul 16, 2025 |
| Jul 14, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -65,203 | $0.00 | $0 | 110,335 | Jul 16, 2025 |
| Jul 15, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -800 | $0.00 | $0 | 109,535 | Jul 16, 2025 |
| Jun 9, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +287,500 | $19.39 | $5.6M | 287,500 | Jun 11, 2025 |
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,824 | $29.52 | $83k | 415,695 | Jan 30, 2025 |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -13,551 | $30.43 | $412k | 418,519 | Jan 23, 2025 |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -6,007 | $29.96 | $180k | 301,408 | Jan 21, 2025 |
| Jan 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +130,662 | $0.00 | $0 | 432,070 | Jan 21, 2025 |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -6,247 | $28.70 | $179k | 307,415 | Jan 14, 2025 |
| Nov 1, 2024 | APLS Apellis Pharmaceuticals, Inc. | JOther Common Stockindirect: Indirect Owner (The Cedric Francois Irrevocable Trust of 2023) | -182,146 | $0.00 | $0 | 472,065 | Nov 1, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.